GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (STU:ORN) » Definitions » Institutional Ownership

Oryzon Genomics (STU:ORN) Institutional Ownership : 0.63% (As of Jun. 10, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oryzon Genomics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Oryzon Genomics's institutional ownership is 0.63%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Oryzon Genomics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Oryzon Genomics's Float Percentage Of Total Shares Outstanding is 0.00%.


Oryzon Genomics Institutional Ownership Historical Data

The historical data trend for Oryzon Genomics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics Institutional Ownership Chart

Oryzon Genomics Historical Data

The historical data trend for Oryzon Genomics can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 0.93 0.93 0.93 0.92 0.90 0.79 0.78 0.76 0.64 0.63

Oryzon Genomics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Oryzon Genomics (STU:ORN) Business Description

Traded in Other Exchanges
Address
Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.